Teleflex enters a 3-year agreement with group purchasing organization Premier for its Arrow dialysis access products.
Teleflex says it won a grant from the U.S. Army worth more than $2 million to develop an anti-microbial orthopedic device using Teleflex's Semprus Sustain coating technology.
Teleflex (NYSE:TFX) said today that it landed a U.S. Army grant for the Semprus Sustain anti-microbial coating technology it was having a hard time with earlier this year.
Teleflex issues a Class I recall of its pediatric anesthesia devices over concerns that certain components could break during use, resulting in serious injury or even death.
Teleflex reportedly plans an expansion of its catheter production operations in the Czech Republic.
Teleflex (NYSE:TFX) reportedly plans to expand its catheter production operations in the Czech Republic, where it already has some 700 employees.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Report: Medtech M&A exits don't hinge on FDA approval; White House rails against Medtronic-style corporate inversions; Smith & Nephew CEO: We've been an M&A target for 10 years; More mega-merger talk from medtech giants; Baxter sheds vaccines biz for $635M
Leadership at Johnson & Johnson and Teleflex weigh in on the multi-billion-dollar mergers that are shifting the landscape of the medical device industry.
MASSDEVICE ON CALL — More medical device giants offered their 2¢ on high-dollar mega-mergers, joining other companies in saying that they aren't planning any billion-dollar buys just yet.
Teleflex gets some Wall Street love after reporting double-digit revenue growth in Q2, beating analysts' expectations and raising its adjusted per-share earnings guidance for the rest of the year.
Wayne, Pa.-based Teleflex (NYSE:TFX) served up some good news today with strong numbers for its 2nd quarter and an increased outlook on the year.
The company posted an 11.4% increase in sales and an 11.3% increase in profits, with adjusted earnings coming in almost 19% higher year-over-year.